DKK1 and rheumatoid arthritis: Including DKK-1 serum quantification in clinical practice for early RA patients may be beneficial to identify patients with potential poor structural outcome who may need close monitoring for development of early bone erosions and rapid adjustment of DMARDs and/or biologic therapy.